Paper Details

  1. Home
  2. Paper Details

Aplastic Anemia and Severe Myelosuppression with Boceprevir or Simeprevir-Containing Hepatitis C Virus Treatment.

Author: BroquetasTeresa, CarriónJose A, CañeteNuria, FerraroMariana, FornsXavier, LensSabela, LondoñoMaría-Carlota, SalarAntonio, SenínAlicia

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

The addition of protease inhibitors (PIs) to peg-interferon (IFN) and ribavirin (RBV) for chronic hepatitis C has improved sustained virological response rates, but severe hematological toxicity, including agranulocytosis and aplastic anemia, has been reported. This report presents cases of severe hematological toxicity associated with PI-based therapies and discusses the potential for a class effect.
Paper Details　
Original Abstract of the Article :
The addition of the new protease inhibitors (PIs) to peg-interferon (IFN) and ribavirin (RBV), approved for chronic hepatitis C, has clearly improved sustained virological response (SVR) rates although several adverse events have been reported with this regimens, including mild hematological toxicit...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/28233734

データ提供：米国国立医学図書館（NLM）

Navigating the Shifting Sands of Hepatitis C Treatment

Hepatitis C virus (HCV) infection, a silent and often persistent threat, can leave individuals feeling lost in a desert of uncertainty. This report explores the potential of new protease inhibitors (PIs) in treating HCV infection, focusing on the observed hematological toxicity associated with these medications. The authors discuss two cases of severe agranulocytosis/aplastic anemia and two additional cases of severe myelosuppression in patients treated with boceprevir, simeprevir, or sofosbuvir-containing regimens.

A New Frontier in Treatment

This report highlights the potential risks associated with the use of new PIs in HCV treatment. The authors emphasize the importance of careful monitoring and vigilant management of hematological parameters in patients receiving these therapies.

A Journey Towards a Cure

The report underscores the importance of ongoing research and development in the field of HCV treatment. As new therapies emerge, it is crucial to thoroughly evaluate their safety and efficacy to ensure that patients receive the best possible care.

Dr. Camel's Conclusion

This report serves as a reminder of the complex landscape of HCV treatment. While new PIs offer hope for a cure, it is essential to remain vigilant about their potential side effects and to monitor patients closely during therapy. The journey towards a cure for HCV infection continues, with each new discovery bringing us closer to a healthier future.

Date :
  1. Date Completed 2017-04-17
  2. Date Revised 2021-09-28
Further Info :

Pubmed ID

28233734

DOI: Digital Object Identifier

S1665-2681(19)30398-9

Related Literature

Article Analysis
・Effects of boceprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.